|
1
|
Adelstein DJ, Li Y, Adams GL, Wagner H Jr,
Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup
phase III comparison of standard radiation therapy and two
schedules of concurrent chemoradiotherapy in patients with
unresectable squamous cell head and neck cancer. J Clin Oncol.
21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wendt TG, Grabenbauer GG, Rödel CM, Thiel
HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C and Schalhorn
A: Simultaneous radiochemotherapy versus radiotherapy alone in
advanced head and neck cancer: a randomized multicenter study. J
Clin Oncol. 16:1318–1324. 1998.PubMed/NCBI
|
|
3
|
Adelstein DJ, Lavertu P, Saxton JP, Secic
M, Wood BG, Wanamaker JR, Eliachar I, Strome M and Larto MA: Mature
results of a phase III randomized trial comparing concurrent
chemoradiotherapy with radiation therapy alone in patients with
stage III and IV squamous cell carcinoma of the head and neck.
Cancer. 88:876–883. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fuwa N, Ito Y, Matsumoto A, Kamata M,
Kodaira T, Furutani K, Sasaoka M, Kimura Y and Morita K: A
combination therapy of continuous superselective intraarterial
carboplatin infusion and radiation therapy for locally advanced
head and neck carcinoma. Phase I study. Cancer. 89:2099–2105. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Posner MR, Hershock DM, Blajman CR,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, Murphy BA, et al: TAX 324 Study Group:
Cisplatin and fluorouracil alone or with docetaxel in head and neck
cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Forastiere AA, Goepfert H, Maor M, Pajak
TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et
al: Concurrent chemotherapy and radiotherapy for organ preservation
in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suzuki M, Ishikawa H, Tanaka A and Mataga
I: Heterogeneity of anticancer drug sensitivity in squamous cell
carcinoma of the tongue. Human Cell. 24:21–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kato T: Phase II study of
CIS-diamminedichloroplatinum (II) by collaborative study. Gan To
Kagaku Ryoho. 9:694–701. 1982.(In Japanese). PubMed/NCBI
|
|
9
|
Noda K, Takeuchi S, Kurihara S, Sugawa T,
Kato T, Ikeda M, Kanazawa K, Tsutsui F, Yamamoto K, Umezu J, et al:
Phase II study of cisplatin in cervical and endometrial carcinomas.
Gan To Kagaku Ryoho. 14:1129–1135. 1987.(In Japanese). PubMed/NCBI
|
|
10
|
Ishibiki K, Kumai K, Kodaira S, Abe O,
Yamamoto K, Oouchi T, Fukaya Y, Kimura K, Takamatsu K, Ootsuka E,
et al: Phase II study with cisplatin in advanced stomach and colon
carcinoma. Cooperative study group of cisplatin for stomach and
colon carcinoma. Gan To Kagaku Ryoho. 16:3185–3193. 1989.(In
Japanese). PubMed/NCBI
|
|
11
|
Kondo T, Kubota T, Tanimura H, Yamaue H,
Akiyama S, Maehara Y, Tanigawa N, Kitajima M and Takagi H:
Cumulative results of chemosensitivity tests for antitumor agents
in Japan. Japan Research Society for Appropriate Cancer
Chemotherapy. Anticancer Res. 20:2389–2392. 2000.PubMed/NCBI
|
|
12
|
Rygaard J and Povlsen CO:
Heterotransplantation of a human malignant tumor to ‘Nude’ mice.
Acta Pathol Microbiol Scand. 77:758–760. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bogden AE, Cobb WR, Lepage DJ, Haskell PM,
Gulkin TA, Ward A, Kelton DE and Esber HJ: Chemotherapy
responsiveness of human tumors as first transplant generation
xenografts in the normal mouse: Six-day subrenal capsule assay.
Cancer. 48:10–20. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kobayashi H, Tanisaka K, Kondo N, Mito Y,
Koezuka M, Yokouchi H, Higashiyama M, Kodama K, Doi O, Yamada M, et
al: Development of new in vitro chemosensitivity test using
collagen gel droplet embedded culture and its clinical usefulness.
Gan To Kagaku Ryoho. 22:1933–1939. 1995.(In Japanese). PubMed/NCBI
|
|
15
|
Kobayashi H, Higashiyama M, Minamigawa K,
Tanisaka K, Takano T, Yokouchi H, Kodama K and Hata T: Examination
of in vitro chemosensitivity test using collagen gel droplet
culture method with colorimetric endpoint quantification. Jpn J
Cancer Res. 92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kobayashi H: Development of a new in vitro
chemosensitivity test using collagen gel droplet culture and image
analysis for clinical usefulness. Recent Results Cancer Res.
161:48–61. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hanatani Y, Kobayashi H, Kodaira S, Takami
H, Asagoe T and Kaneshiro E: An in vitro chemosensitivity test for
gastric cancer using collagen gel droplet embedded culture. Oncol
Rep. 7:1027–1033. 2000.PubMed/NCBI
|
|
18
|
Araki Y, lsomoto H, Matsumoto A, Kaibara
A, Yasunaga M, Hayashi K, Yatsugi H and Yamauchi K: An in vitro
chemosensitivity test for colorectal cancer using collagen-gel
droplet embedded cultures. Kurume Med J. 46:163–166. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shintani S, Hino S, Nakashiro K and
Hamakawa H: Clinical trial of chemotherapy identified according to
chemosensitivity assay for oral cancer patients with unresectable
recurrent lesions. Gan To Kagaku Ryoho. 33:357–360. 2006.(In
Japanese). PubMed/NCBI
|
|
20
|
Matsumoto Y, Tamiya T and Nagano S:
Resistance to topoisomerase II inhibitors in human glioma cell
lines overexpressing multidrug resistant associated protein (MRP)
2. J Med Invest. 52:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Selvakumaram M, Pisarcik DA, Bao R, Yeung
AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing
the nucleotide excision repair pathway in ovarian cancer cell
lines. Cancer Res. 63:1311–1316. 2003.PubMed/NCBI
|
|
22
|
Bartolucci R, Wei J, Senchez JJ,
Perez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto
T, et al: XPG mRNA expression levels modulate prognosis in resected
non-small-cell lung cancer in conjunction with BRCA1 and ERCC1
expression. Clin Lung Cancer. 10:47–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JS, Yoon S Young, Kim JM, Yeom YI,
Kim YS and Kim NS: Identification of novel genes associated with
the response to 5-FU treatment in gastric cancer cell lines using a
cDNA microarray. Cancer Lett. 214:19–33. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koezuka M, Kondo N, Kobayashi H, Hara S,
Yasutomi M, Nishida S, Hashimoto S and Asano H: Drug sensitivity
test for human cancer-cells using collagen gel embedded culture and
image analysis. Int J Oncol. 2:953–959. 1993.PubMed/NCBI
|
|
25
|
Nagai N, Minamikawa K, Mukai K, Hirata E,
Komatsu M and Kobayashi H: Predicting the chemosensitivity of
ovarian and uterine cancers with the collagen gel droplet culture
drug-sensitivity test. Anticancer Drugs. 16:525–531. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Inuyama Y and Takeda C: A cooperative
phase II study of cisplatin in patients with head and neck cancer.
Gan To Kagaku Ryoho. 13:232–238. 1986.(In Japanese). PubMed/NCBI
|
|
27
|
Jacobs C, Lyman G, Velez-García E, Sridhar
KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH,
Schacter L, et al: A phase III randomized study comparing cisplatin
and fluorouracil as single agents and in combination for advanced
squamous cell carcinoma of the head and neck. J Clin Oncol.
10:257–263. 1992.PubMed/NCBI
|
|
28
|
Inaba M, Kobayashi T, Tashiro T and
Sakurai Y: Pharmacokinetic approach to rational therapeutic dose
for human tumor-bearing nude mice. Jpn J Cancer Res. 79:509–516.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Inaba M: Pharmacokinetic approach to the
improvement of clinical predictability in the preclinical test for
antitumor agents. Gan To Kagaku Ryoho. 18:1449–1456. 1991.(In
Japanese). PubMed/NCBI
|
|
30
|
Geran RI, Greenberg NH, Macdonald MM, et
al: Protocols against animal tumors and other biological systems.
Cancer Chemother Rep. 3:51–57. 1972.
|
|
31
|
Kawamura M, Inoue Y, Oyama T and Kobayashi
K: Chemosensitivity test for uresectable non-small cell lung
cancer. Nihon Geka Gakkai Zasshi. 103:229–232. 2002.(In Japanese).
PubMed/NCBI
|
|
32
|
Takamura Y, Kobayashi H, Taguchi T,
Motomura K, Inaji H and Noguchi S: Prediction of chemotherapeutic
response by collagen gel droplet embedded culture-drug sensitivity
test in human breast cancers. lnt J Cancer. 98:450–455. 2002.
|
|
33
|
Kondo T, lmamura T and lchibashi H: In
vitro test for sensitivity of tumor to carcinostatic agents. Gan.
57:113–121. 1966.PubMed/NCBI
|
|
34
|
Salomon SE, Hamburger AW, Soehnlen B,
Durie BG, Alberts DS and Moon TE: Quantitation of differential
sensitivity of human-tumor stem cell to anticancer drugs. N Engl J
Med. 298:1321–1327. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kobayashi H: CD-DST (Collagen gel droplet
embedded culture drug sensitivity test). Oncology Chemotherapy.
16:231–235. 2000.
|
|
36
|
Shintani S, Hino S, Nakashiro K and
Hamakawa H: Clinical trial of chemotherapy identified according to
chemosensitivity assay for oral cancer patients with unresectable
recurrent lesions. Gan To Kagaku Ryoho. 33:357–360. 2006.PubMed/NCBI
|
|
37
|
Rosell R, Taron M, Barnadas A, Scagliotti
G, Sarries C and Roig B: Nucleotide excision repair pathways
involved in Cisplatin resistance in non-small-cell lung cancer.
Cancer Control. 10:297–305. 2003.PubMed/NCBI
|
|
38
|
Reardon JT, Vaisman A, Chaney SG and
Sancar A: Efficient nucleotide excision repair of cisplatin,
oxaliplatin, and
Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216)
platinum intrastrand DNA diadducts. Cancer Res. 59:3968–3971.
1999.PubMed/NCBI
|
|
39
|
Takenaka T, Yoshino I, Kouso H, Ohba T,
Yohena T, Osoegawa A, Shoji F and Maehara Y: Combined evaluation of
Rad51 and ERCC1 expressions for sensitivity to platinum agents in
non-small cell lung cancer. Int J Cancer. 121:895–900. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Simon GR, Sharma S, Cantor A, Smith P and
Bepler G: ERCC1 expression is a predictor of survival in resected
patients with non-small cell lung cancer. Chest. 127:978–983. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fukushima M, Nomura H, Murakami Y,
Shirasaka T and Aiba K: Estimation of pathways of 5-fluorouracil
anabolism in human cancer cells in vitro in vivo. Gan To Kagaku
Ryoho. 23:721–731. 1996.(In Japanese). PubMed/NCBI
|
|
42
|
Sakamoto K, Sugimoto Y, Miyadera K, Oka T
and Fukushima M: Preparation of anti-OPRT antibody for
immunochemical detection. Gan To Kagaku Ryoho. 32:653–658. 2005.(In
Japanese). PubMed/NCBI
|
|
43
|
Ishida H, Shirakawa K, Ohsawa T, Sobajima
J, Hayashi Y, Nakada H, Yokoyama M and Hashimoto D: Expression of
mRNA levels of thymidilate synthase, dihydropyrimidine
dehydrogenase, and orotate phosphoribosyltransferase of colorectal
cancer-relationships among mRNA levels in association with response
to 5-FU based treatment. Gan To Kagaku Ryoho. 32:1929–1934.
2005.(In Japanese). PubMed/NCBI
|
|
44
|
Yamada T, Tanaka N, Yokoi K, Ishikawa N,
Seya T, Kanazawa Y, Shirakawa T, Ohkawa K, Koizumi M, Ohaki Y, et
al: Correlation between clinical pathologic factors and enzymatic
activity of orotate phosphoribosyl transferase (OPRT),
dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS)
in colorectal cancer. Gan To Kagaku Ryoho. 33:789–793. 2006.(In
Japanese). PubMed/NCBI
|
|
45
|
Watanabe M, Satomi T, Matuda K, et al:
Relationship between expression of enzymes activating
fluoropyrimidine anti-tumor agents and response to the agents in
oral squamous cell carcinoma. Japanese Journal of Head and Neck
Cancer. 34:498–502. 2008.
|
